Rhodioloside

Rhodioloside, also called salidroside, is a phenylpropanoid glycoside extracted primarily from Rhodiola rosea root that acts on monoamine neurotransmitter systems and stress-response pathways. Despite its structural activity and traditional adaptogenic context, no human clinical trials have isolated rhodioloside alone to confirm therapeutic benefits independent of whole-plant extracts.

Origin & History

Rhodioloside, also known as salidroside, is a bioactive phenolic glycoside extracted primarily from the roots of Rhodiola rosea, a plant native to high-altitude regions. It is produced through enzymatic hydrolysis, microwave or infrared-assisted extraction, and purification via macroporous resins, achieving >96% purity.

Historical & Cultural Context

Rhodiola rosea has been studied for its chemical composition in Chinese medicine as Radix Rhodiolae and is noted as an 'effective adaptogenic drug.' However, specific historical uses or traditional dosing for rhodioloside are not detailed in the available research.

Health Benefits

• No clinical benefits documented - the research dossier contains no human clinical trials or evidence of health benefits
• Traditional adaptogenic use suggested but not clinically validated in the available research
• Chemical extraction methods optimized but therapeutic effects remain unstudied
• Raw root concentrations of 0.84-0.89% identified but clinical significance unknown
• Purification to 96.5-99% achieved but efficacy data absent

How It Works

Rhodioloside (salidroside) is thought to inhibit monoamine oxidase A and B enzymes, thereby increasing synaptic availability of serotonin, dopamine, and norepinephrine. It also appears to activate the PI3K/Akt and AMPK signaling pathways, which regulate cellular stress responses and mitochondrial biogenesis. Additionally, preclinical data suggest it modulates HIF-1α (hypoxia-inducible factor) expression and suppresses pro-inflammatory cytokines such as TNF-α and IL-6 via NF-κB pathway inhibition.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for rhodioloside were found in the research dossier. The available literature focuses exclusively on extraction and purification methods rather than therapeutic applications.

Clinical Summary

No human clinical trials have been conducted using isolated rhodioloside as the sole intervention; existing clinical research on Rhodiola rosea uses standardized whole-root extracts containing multiple compounds including rosavins alongside salidroside. Several randomized controlled trials on Rhodiola extract (n=56–100 participants) have reported reductions in fatigue and stress markers, but these outcomes cannot be attributed to rhodioloside specifically. Preclinical in vitro and rodent studies demonstrate neuroprotective and anti-fatigue effects at doses of 10–100 mg/kg, yet translating these findings to human dosing remains unvalidated. The current evidence base is insufficient to make efficacy claims for rhodioloside as an isolated ingredient.

Nutritional Profile

Rhodioloside (also known as salidroside or p-hydroxyphenethyl-β-D-glucopyranoside) is a phenylpropanoid glycoside compound, not a conventional nutritional ingredient — it contains no meaningful macronutrients, vitamins, minerals, or dietary fiber in functional quantities. Molecular weight: 300.31 g/mol. Chemical formula: C14H20O7. It is the primary bioactive glycoside extracted from Rhodiola rosea root, occurring at raw root concentrations of approximately 0.84–0.89% dry weight. Purified isolates can reach concentrations of 95–98% purity via HPLC-grade extraction. The compound consists structurally of a tyrosol aglycone linked to a glucose moiety via a β-glucosidic bond. As a compound isolate, it provides negligible caloric value (estimated <1 kcal per typical research dose of 1–50 mg). Bioavailability data from animal models suggests oral absorption with hepatic metabolism, though human pharmacokinetic data remains limited. It is water-soluble due to its glycoside structure, which enhances dissolution compared to its aglycone form tyrosol. No protein, lipid, or carbohydrate nutritional content is applicable at functional dosing levels. Trace residual solvents may be present depending on extraction methodology (ethanol or methanol-based extraction protocols are commonly documented).

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials have been conducted. Raw Rhodiola roots contain 0.84-0.89% salidroside, but therapeutic doses have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient data - no synergistic compounds identified in research

Safety & Interactions

Rhodioloside has not been independently evaluated for safety in formal human toxicology studies, though it is consumed indirectly through Rhodiola rosea supplements which have a generally favorable short-term safety profile. Potential drug interactions include additive effects with MAO inhibitors and serotonergic medications due to its monoamine-modulating activity, raising risk of serotonin syndrome at high doses. Rhodiola-based products are typically advised against during pregnancy and lactation due to insufficient safety data, and this caution extends to isolated rhodioloside. Individuals taking antidiabetic medications or anticoagulants should exercise caution, as preclinical data suggest possible effects on blood glucose and platelet aggregation.